OIG Releases Decision on Diagnostic Test Sporsorship

Note: The headline above preserves the original spelling requested. The analysis below discusses HHS-OIG guidance on sponsored diagnostic and genetic testing programs.

When the Office of Inspector General releases a fresh decision on diagnostic test sponsorship, health care lawyers do not exactly throw confetti. But they do sit up straighter, refill the coffee, and start underlining things. That is because sponsored testing lives in one of the trickiest corners of health care compliance: it can improve patient access and speed up diagnosis, yet it can also look suspiciously like a clever way to steer prescriptions.

The latest OIG thinking shows that sponsored testing is not automatically forbidden, but it absolutely is not a free-for-all either. In its favorable Advisory Opinion 24-12, OIG blessed a pharmaceutical manufacturer’s program to sponsor genetic testing, related genetic counseling, and disease-state awareness education for certain hereditary conditions linked to kidney stones. Later, in Advisory Opinion 25-07, OIG also approved a more targeted companion laboratory test arrangement that helps determine whether a patient may be an appropriate candidate for a specific drug. Put plainly: OIG did not throw open the gates, but it did leave a carefully supervised side door unlocked.

For drugmakers, laboratories, providers, compliance teams, and patients, that matters a lot. These opinions reveal what OIG sees as acceptable guardrails, what still makes the agency nervous, and what kinds of facts can turn a patient-access program into a fraud-and-abuse headache with a seven-figure price tag. And yes, in this area, the line between “helpful access tool” and “please call outside counsel immediately” can be thinner than a lab requisition form.

What OIG Actually Approved

The most important starting point is this: OIG did not say sponsored diagnostic testing is risk-free. In Advisory Opinion 24-12, the agency expressly recognized that the arrangement implicated the federal Anti-Kickback Statute and the beneficiary inducement civil monetary penalty rules. Even so, OIG concluded it would not impose administrative sanctions because the program, as structured, presented a sufficiently low risk of fraud and abuse.

The arrangement involved a manufacturer with an FDA-approved drug for one subtype of an ultra-rare genetic condition associated with recurrent kidney stones and chronic kidney disease. The sponsor proposed to pay for one of several commercially available genetic testing panels, an additional assay if the result was inconclusive, optional genetic counseling, and general disease-awareness education. That sounds generous, and in compliance land, generous is often just another word for “please explain yourself in writing.”

OIG was persuaded because several safeguards were built into the program. Patients had to meet narrow, clinically defined eligibility criteria. A licensed health care professional had to attest that the patient met those criteria. The tests were commercially available rather than custom-built as a marketing gadget. The sponsor said neither patients nor payors, including federal health care programs, would be billed for the testing or counseling. Providers also could not charge collection fees connected to the program. In addition, the sponsor would pay fixed, fair-market-value fees to the lab and related service providers.

Just as important, the sponsor did not receive identifiable patient data or information identifying the providers ordering the tests. It received only limited, de-identified, aggregate operational data. Genetic counselors were prohibited from discussing treatment options. The public-facing educational materials were unbranded and did not pitch the sponsor’s drug. That last point matters more than it may seem. When an “education” page starts sounding like a sales brochure wearing glasses, regulators tend to notice.

Then came Advisory Opinion 25-07, which pushed the conversation one step further. There, OIG approved a program in which a pharmaceutical manufacturer sponsored a companion laboratory test for eligible patients before a provider could prescribe a certain drug. This was a tighter relationship between test and therapy than in the earlier rare-disease opinion. Even so, OIG again issued a favorable opinion under the Anti-Kickback Statute analysis, while concluding that the arrangement did not generate prohibited remuneration under the beneficiary inducement rule. The message was subtle but important: OIG may tolerate a closer clinical connection when the facts show the test is being used to identify appropriate patients, not to create a marketing pipeline.

Why the Opinions Matter So Much

These decisions matter because sponsored testing sits at the crossroads of several real-world pressures. Patients with rare conditions often face long diagnostic delays, spotty insurance coverage, and costly testing. Manufacturers, meanwhile, want earlier and more accurate identification of patients who may benefit from their therapies. Laboratories want business, providers want practical tools, and payors want to avoid paying for unnecessary care. Put those interests in one room, and you either get innovation or a compliance seminar. Sometimes both.

OIG’s opinions show that the agency recognizes the legitimate clinical value of testing, especially where a condition is rare, symptoms overlap with more common disorders, and testing may help rule out disease as much as diagnose it. In Advisory Opinion 24-12, the rarity of the condition and the narrow design of the testing panels helped OIG conclude the arrangement posed a lower risk of overutilization. In other words, OIG was less worried that free testing would trigger a stampede because the program was aimed at a very specific clinical problem, not a broad patient population with vague symptoms.

At the same time, OIG also made clear that favorable treatment is highly fact-specific. There is still no broad regulatory safe harbor for manufacturer-sponsored diagnostic testing. That means these opinions are helpful guideposts, not magic shields. A company cannot wave Advisory Opinion 24-12 around like a hall pass and assume every free-testing program is now blessed. OIG practically said the quiet part out loud: change the facts, and the answer may change too.

The Legal Framework Behind the Drama

Anti-Kickback Statute

The Anti-Kickback Statute is the main reason sponsored testing gets such close scrutiny. If a company gives something of value to induce the ordering, purchasing, or recommending of items or services reimbursable by a federal health care program, trouble can follow. Free tests, free counseling, free sample logistics, and valuable data can all count as remuneration. OIG said exactly that in Advisory Opinion 24-12: the free test, possible follow-up assay, and counseling carried value for both patients and providers.

Beneficiary Inducement CMP

OIG also looked at the beneficiary inducement rules, which prohibit offering remuneration likely to influence a Medicare or Medicaid beneficiary’s choice of provider, practitioner, or supplier. In 24-12, OIG said the arrangement implicated that rule because free testing and counseling could influence a patient’s follow-up care. In 25-07, however, OIG reached a different conclusion under that specific provision, showing once again that details matter. A lot.

The Guardrails OIG Clearly Likes

If there is a compliance recipe here, it is not exactly simple, but OIG has given the industry a fairly readable ingredient list.

Narrow, clinical eligibility rules

OIG likes programs that are limited to patients with clearly defined clinical criteria. Broad eligibility invites suspicion that a program is really a fishing expedition dressed up as patient support.

No billing games

Neither patients, payors, nor federal programs should be billed for the sponsored testing components. Providers should not use the program as a side door for charging additional related fees that the sponsor is supposedly covering.

Commercially available tests

OIG takes comfort when the test is already commercially available and not a custom-built product designed purely to serve one manufacturer’s sales strategy.

Data walls

This is the big one. The sponsor should not get patient-identifiable or provider-identifiable data that could be used for targeted marketing. Aggregate and de-identified operational data may be acceptable, but identifiable data can turn a compliance team’s blood pressure into a laboratory value of its own.

Unbranded education and limited field involvement

Educational materials should stay educational. Unbranded disease awareness is much easier to defend than materials that subtly, or not so subtly, push a product. OIG also looks more favorably on programs where sales teams are kept at arm’s length from testing decisions and related data.

Fair-market-value payments to labs

Flat fees set in advance and tied to legitimate services help reduce the appearance that labs are being rewarded for referrals or influence.

Where OIG Still Sees Danger

The opinions are favorable, but the warnings are loud. OIG said it likely would have reached a different conclusion if the sponsor had been able to use the program’s data to target marketing or if there had been a more direct nexus between the free test and the purchase of the drug. That phrase, “more direct nexus,” is the compliance equivalent of hearing ominous music in the background.

What does that mean in practice? It means a sponsored testing program becomes riskier when the manufacturer can identify which doctor ordered the test, which patient tested positive, or which account is suddenly ripe for a well-timed sales call. It becomes riskier when the educational campaign is really a demand-generation campaign. It becomes riskier when free testing is rolled out so broadly that it looks less like medical support and more like customer acquisition.

And it becomes especially risky when the company buys results data or otherwise uses testing information to market its drug. That is not a hypothetical concern. The Department of Justice has already shown it is willing to bring cases in this area.

The Enforcement Backdrop: Why Everyone Reads the Footnotes Twice

Recent settlements explain why these OIG opinions are being read with highlighters and mild anxiety. In late 2023, Ultragenyx agreed to pay $6 million to resolve allegations that it paid for free genetic tests and bought result information to induce prescriptions of Crysvita. The government alleged the company used testing information, including provider-related information, as part of its marketing efforts.

Then, in late 2024, QOL Medical and its CEO agreed to pay $47 million to resolve allegations involving free Carbon-13 breath testing services tied to claims for Sucraid. According to DOJ, the company distributed free test kits to providers for patients with common gastrointestinal symptoms and used the testing setup in a way the government said crossed into kickback territory. DOJ also alleged the breath test did not specifically diagnose the rare condition the drug treats.

Those enforcement actions help explain OIG’s caution. The agency is not rejecting sponsored testing outright. It is drawing a distinction between testing programs structured to improve diagnosis and access, and testing programs that also function as lead-generation engines for product sales. Same neighborhood, very different houses.

What This Means for Manufacturers, Labs, and Providers

For manufacturers, the lesson is not “go forth and sponsor every diagnostic under the sun.” The lesson is to build programs backwards from compliance risk. Start with the clinical need. Define the patient population narrowly. Separate disease awareness from brand promotion. Limit the data flow. Keep sales teams out of operational details. Pay fair-market-value fees. Ban third-party billing. Document everything. Then document the documentation, because this is health care compliance and nobody has ever been accused of keeping too few records right before an investigation.

For laboratories, these opinions are a reminder that they are not passive vendors in the background. Labs should watch their contracts, billing practices, data-sharing rules, and communications very carefully. A lab that provides more information than the arrangement allows, or markets the program too aggressively, can transform a sponsor’s “favorable opinion” into a future cautionary tale.

For providers, the opinions are good news with strings attached. Sponsored testing may expand access for patients who would otherwise struggle to get the right test, especially in rare-disease settings or in precision medicine contexts. But providers still need to assess clinical appropriateness independently. They cannot let a free test make the treatment decision for them. If the program’s paperwork feels like a maze, that is not necessarily a bug; it may be the compliance feature keeping the whole thing alive.

What Patients Should Take Away

Patients should not hear “sponsored testing” and immediately assume something improper is happening. In many cases, these programs can help shorten the diagnostic odyssey, reduce out-of-pocket cost, and get the right information to the treating clinician faster. That can be a very big deal when symptoms are vague, the disease is rare, or standard testing paths are slow and unreliable.

But patients should also understand why guardrails matter. If a test is free because it genuinely helps identify or rule out a condition, that is one thing. If it is free because someone wants to know exactly who might be prescribed a specific drug next month, that is something else entirely. OIG’s recent decisions try to preserve the first scenario while discouraging the second.

The Bigger Picture: OIG Is Building a Case-by-Case Playbook

Viewed together, Advisory Opinions 22-06, 24-12, and 25-07 suggest OIG is building a cautious, fact-specific playbook rather than issuing a sweeping policy blessing. The agency appears willing to approve sponsored testing when the clinical rationale is strong, the patient population is appropriately limited, and the arrangement is insulated from overt sales and marketing abuse. It appears far less willing to tolerate data-rich programs that help a manufacturer find prescribers, identify patients, or create a shortcut from free testing to reimbursed drug utilization.

That means the future of diagnostic test sponsorship will likely be defined less by broad slogans and more by operational design. Tiny details will keep doing very heavy lifting: who sees the data, who pays the lab, who can answer questions, whether materials are branded, whether providers can bill, whether the test is independently valuable, and whether the arrangement truly supports diagnosis rather than merely accelerating product uptake.

In plain English, OIG’s decision is neither a green light for everybody nor a red light for everybody. It is more like a flashing yellow with a long instruction manual attached.

Experiences From the Real World of Sponsored Diagnostic Testing

Across the industry, the lived experience of sponsored diagnostic testing tends to be messy, human, and far less glamorous than a polished policy memo makes it sound. For patients, the experience often starts with frustration. They may have symptoms for years, bounce between specialists, run ordinary tests that come back inconclusive, and still have no clear answer. When a provider finally mentions a sponsored genetic or diagnostic test, the reaction is often a mix of relief and suspicion: relief because the test may be affordable, suspicion because “free” in health care rarely feels simple. Patients want to know who is paying, why they are paying, whether the results will stay private, and whether this test is really about their health or about someone’s quarterly sales meeting.

Providers have their own version of the experience. Many clinicians appreciate programs that remove financial barriers for patients, especially when the disease is rare and insurance coverage is patchy. But they also know that every “easy access” program tends to arrive with forms, attestations, portal logins, consent language, and enough operational fine print to make a printer weep. A doctor may think, “Great, my patient can finally get the right test,” and then spend the next twenty minutes figuring out whether the kit goes to the office, the patient’s home, or a pathology lab across town. None of that makes the headlines, but it is where compliance succeeds or fails.

Laboratories often sit in the middle, quietly doing the hard work of making the arrangement function. They have to manage logistics, prevent duplicate billing, keep sponsor data separate, and train staff not to say the wrong thing to the wrong audience. In practice, the difference between a compliant arrangement and a problematic one may come down to whether a customer service representative treats a test as a clinical service or as a marketing opportunity. That is a lot of responsibility for one phone call on a Tuesday afternoon.

Then there are the manufacturer’s internal teams. Compliance departments tend to approach these programs like bomb-disposal experts: slow hands, careful steps, no surprises. Commercial teams may view the same program as a way to raise awareness of underdiagnosed disease. Medical affairs may see scientific value. Market access teams may focus on treatment pathways. Everyone thinks they are being reasonable, which is exactly why these programs generate so many meetings. The phrase “we only need limited data” has probably caused more internal panic than anyone admits. In this space, one extra data field can be the difference between “patient access initiative” and “government exhibit number twelve.”

That is why OIG’s recent opinions resonate so strongly. They reflect the real push and pull that companies, labs, and providers experience every day: the desire to help patients sooner, the temptation to learn more from the testing process, and the need to stop that learning from becoming targeting. The most successful programs are usually the ones that accept this tension instead of pretending it does not exist. They are designed with restraint, reviewed with skepticism, and operated with the understanding that in health care compliance, a good idea still needs very good boundaries.

Conclusion

OIG’s decision on diagnostic test sponsorship is best understood as a carefully measured approval, not a blank check. The agency has shown it will tolerate certain manufacturer-sponsored testing arrangements when they are narrowly tailored, clinically justified, operationally disciplined, and insulated from marketing misuse. At the same time, recent DOJ settlements make clear that sponsored testing can become legally toxic when free services and results data are used to drive prescriptions or identify prescribers.

That combination of favorable opinions and aggressive enforcement is the real story. OIG is not trying to kill sponsored testing. It is trying to separate legitimate patient-access programs from disguised sales tactics. Companies that understand that difference and build around it have a path forward. Companies that ignore it may discover that “free test” can become an extremely expensive phrase.